Introduction {#Sec1}
============

Malaria is a neglected tropical disease caused by the protozoan of the genus and transmitted by the female (*Culicidae*) mosquitoes (França et al. [@CR35]). Probably originated in Africa, malaria has been plaguing the humanity for millennia, which can be inferred from documents of ancient civilizations that preceded the Christian era (Egyptians, Chinese, Mesopotamian, Hindus, Greeks, and Romans). Important figures in the human history, such as Pharaoh Tutankhamun and his family (1324 BC), Saint Augustine (579 BC), Dante Alighieri (1321 AD), and Charles V of the Holy Roman Germanic Empire (1558 AD), were affected by severe intermittent fevers (Celli [@CR21]; Bruce-Chwatt [@CR19]; Hawass et al. [@CR43]; Fiocruz [@CR32]).

The great navigations and the consequent territorial conquests were the perfect opportunity for malaria to spread to other regions of the planet, being considered one of the most devastating diseases of North American colonies between the XVI and the XVIII centuries (Duffy [@CR31]; Ackerknecht [@CR2]; Russell [@CR78]). At the XVIII century, Italians thought that the symptoms of intermittent fever were due to unhealthy air---"*mal aire*"---and that expression gave rise to the current name of the disease, malaria. In South America, this disease arrived through the ships that brought the slaves to work mainly in Brazil (Yalcindag et al. [@CR97]). At the XVII century, as the mortality increased, South American, Indians, and Jesuit priests started using teas and beverages prepared with *Cinchona*sp. as treatment (Lee [@CR48]; Ockenhouse et al. [@CR69]). In 1820, Pierre Pelletier and Joseph Caventau isolated quinine from *Cinchona* sp., proved its antimalarial effect, and in the next year, quinine and quinine sulfate were commercially available as the first antimalarial drugs (Cunico et al. [@CR27]). Despite the discovery of an effective active principle, it took some decades to elucidate the causes of malaria. It was in 1880 that the French physician Charles Alphonse Laveran observed the malaria-causing protozoa in red blood cells of one of his patients. Between 1897 and 1899, Italian researchers Amico Bignami, Giuseppe Bastianelli, Battista Grassi, and the English physician Ronald Ross identified the female of the *Anopheles* mosquito as the transmitter of *Plasmodium* protozoan to the mammals and defined its life cycle, for which he was awarded Nobel Prizes in 1902 and 1907 (Keeble [@CR45]; Despomnier et al. [@CR29]; FioCruz [@CR32]).

Up to the I World War, quinine was the only drug used to treat malaria. The difficulty to obtain the bark of *Cinchona* motivated the Germans to develop, in 1920, a synthetic molecule, 9-aminoacridine, that has been marketed since 1930 by the trade name Atabrine (Wallace [@CR01]). Despite the advances, the countries involved in the I World War reported large decrease in their populations due to malaria. In the XI Pan American Sanitary Conference in 1942, malaria was identified as the continent's most devastating disease (Rocha et al. [@CR77]).

In the II World War, also driven by the inherent difficulties for the extraction of quinine from the bark of *Cinchona*, the United States started working in 1942 on an alternative synthetic drug, Atabrine (Curico et al. [@CR27]). A couple of years later, american researchers in collaboration with pharmaceutical industries attempted to produce a synthetic quinine, but technical drawbacks and the large-scale production costs made this attempt impossible (Lee [@CR48]).

The failures in the laboratory synthesis of quinine greatly motivated researches for the prospection of new antimalarial drugs such as Amodiaquine, Primaquine, Proguanil, Pyrimethamine, and Chloroquine (Boss et al. [@CR17]; Ockenhouse et al. [@CR69]; Silva et al. [@CR85]). Chloroquine has been highlighted among these drugs due to its efficiency, low production costs, low toxicity, and the possibility of being consumed by pregnant women. These advantages made chloroquine the first choice in the treatment of malaria (Robert et al. [@CR76]; Silva et al. [@CR85]).

During the Korean (1950--1953) and Vietnam (1950--1957) wars, the US Army observed that some malaria patients did not respond to chloroquine. Again, a new drug prospection program was conducted, in which Dapsone, Pyrimethamine, Sulfadoxine, Sulfalene, Mefloquine, and Halofantrine were developed (Boss et al. [@CR17]; Foley et al. [@CR33]; Ockenhouse et al. [@CR69]; Nzila et al. [@CR68]).

More recently, it was observed that the number of *Plasmodium* strains resistant to the drugs available on the market has increased dramatically, and researches for the discovery of new antimalarial drugs have become increasingly necessary. Some emerging countries like Brazil, India, and China have invested extensively in researches for the treatment of neglected tropical diseases, especially malaria. In the 1970s, Chinese researchers presented artemisinin and its semisynthetic derivatives (Artemether, Arteether, Artesunate, Artemisinic acid, and Dihydroartemisin) as potential antimalarial drugs (Li et al. [@CR52]; Prince [@CR72]; Haynes [@CR44]). The success of these drugs in the treatment of malaria is due to the fact that the *Plasmodium* strains have still little or no resistance to them.

Currently, statistics related to the number of malaria deaths are lower than in previous decades, with a decrease of approximately 52% in the last 15 years (Fig. [8.1](#Fig1){ref-type="fig"}). However, malaria is still present in 108 countries, and in 2015, it was estimated that 212 million people were affected by the disease, with most of the cases concentrated in Southeast Asia, sub-Saharan Africa, and Amazon due to their tropical or subtropical climates that favor the survival and reproduction of *Anopheles* mosquitoes. Also, countries with the highest number of malaria cases are in regions with poor sanitary conditions that also favor the reproduction and development of the malaria vector.Fig. 8.1Number of malaria deaths in the world in the last 15 years (*Source* World Health Organization [@CR94])

Projects such as the "Roll Back Malaria Partnership" (RBM) must invest approximately 93 billion euros until 2030 ([www.rollbackmalaria.org](http://www.rollbackmalaria.org)) for the treatment and total eradication of malaria. However, the success of such initiatives can be compromised once again by problems caused by the resistance of *Plasmodium* lineages. For this reason, research for the development of new antimalarial drugs must be constant. Recently, metal-based drugs have been actively explored for the treatment of a variety of parasites, with an important effect in the treatment of malaria. The following paragraphs aim to present the state-of-the-art of such strategy.

General Aspects of Malaria: The Mechanisms of Action of Classic Drugs and the Resistance of the Protozoan {#Sec2}
=========================================================================================================

Malaria is a protozoan infection caused by *Plasmodium* (*P. falciparum, P. vivax, P. ovale* and *P. malariae*), with *P. falciparum* being the most dangerous form of the disease due to the related highest rates of complications and mortality. The main vector to humans and other mammals is mosquitoes of the genus *Anopheles*, which comprises more than 400 species, with only a few epidemiologically important. These mosquitoes have nocturnal habits, and only females feed on blood and are responsible for the transmission of the *Plasmodium* (Rabinovitch et al.[@CR74]; FioCruz [@CR32]).

The life cycle of the protozoan is divided between a host and an insect vector, as briefly described below and illustrated schematically in Fig. [8.2](#Fig2){ref-type="fig"}. (**I**) By stinging the host, the sporozoite form of *Plasmodium*, lodged in the mosquito's salivary glands, is injected into the bloodstream until it reaches the liver. (**II**) In hepatic cells, the sporozoites reproduce asexually generating other cells called merozoite (not all merozoites reproduce asexually, some develop sexually). (**III**) The merozoites destroy the erythrocytes, causing anemia in the host and initiating a series of reproductive cycles. (**IV**) Some merozoites will become immature gametocytes, precursors of male and female gametes. (**V**) By re-stinging the host, the gametocytes will be collected and matured in the mosquito's digestive system. (**VI**) The fusion of gametocytes will result in zygotes (also named as ookinetes) that will subsequently be converted into sporozoites, which migrate to the salivary glands of the mosquito, thus initiating a new infectious cycle (Rabinovitch et al. [@CR74]; Cunico et al. [@CR27]; FioCruz [@CR32]).Fig. 8.2*Plasmodium* life cycle. The stages **I**--**IV** occur in the host cells and stages **V** and **VI** occur in the *Anopheles* mosquito

The knowledge of the *Plasmodium* life cycle is of fundamental interest in the selection and administration of drugs for the treatment of the infected host. According to Korolkovas and Burckhalter ([@CR47]), the antimalarials commonly used act on the evolutionary stage of the parasite and can be classified as follows:

(I)Blood schizonticides or suppressive agents: drugs that act on the asexual forms of the parasite found in the bloodstream;(II)Tissue schizonticides: drugs that act on the asexual forms of the parasite found in the tissues;(III)Gametocytes: drugs that act on the sexual forms of the parasites;(IV)Sporonticides: drugs that act indirectly on the vegetative forms found in the mosquito vector through gametocytes;(V)Sporozoiticides: drugs that act on the forms of the parasite infecting the host.

The effects of the above antimalarial drugs on parasite cells are variable according to the infecting species; however, these drugs may act as hemozoin production inhibitors, folic acid synthesis inhibitors, transcription inhibitors or inhibitors of the mitochondrial respiratory chain, transport proteins inhibitors, and genetic material modifiers (Cunico et al. [@CR27]; Rai et al. [@CR75]). Table [8.1](#Tab1){ref-type="table"} shows the main classes of antimalarial used, their molecular structures, and their effects on the parasite.Table 8.1Main classes of antimalarial drugs used in the treatment and their effects on the parasiteClasses of antimalarial drugs and effects on the parasiteMain Drugs used on treatmentAryl-alcohols: hemozoin production inhibitors**Quinine**![](454651_1_En_8_Figa_HTML.gif){#d29e667}**Mefloquine**![](454651_1_En_8_Figb_HTML.gif){#d29e680}**Halofantrine**![](454651_1_En_8_Figc_HTML.gif){#d29e693}**Pyronaridine**![](454651_1_En_8_Figd_HTML.gif){#d29e706}**Lumefantrine**![](454651_1_En_8_Fige_HTML.gif){#d29e719}Artemisinin and derivatives: hemozoin production inhibitors, mitochondrial respiratory chain inhibitors, and transport proteins**Artemisin**![](454651_1_En_8_Figf_HTML.gif){#d29e735}**Artemether**![](454651_1_En_8_Figg_HTML.gif){#d29e748}**Arteether**![](454651_1_En_8_Figh_HTML.gif){#d29e761}**Artesunate**![](454651_1_En_8_Figi_HTML.gif){#d29e774}**Artenilic acid**![](454651_1_En_8_Figj_HTML.gif){#d29e787}**Dihydroartemisin**![](454651_1_En_8_Figk_HTML.gif){#d29e800}Biguanides and derivatives: folic acid synthesis inhibitors**Chloroproguanil**![](454651_1_En_8_Figl_HTML.gif){#d29e817}**Cyclochloroproguanil**![](454651_1_En_8_Figm_HTML.gif){#d29e830}Naphthoquinones: mitochondrial respiratory chain inhibitors**Atovaquone**![](454651_1_En_8_Fign_HTML.gif){#d29e846}**Ubiquinone**![](454651_1_En_8_Figo_HTML.gif){#d29e859}Quinolines: hemozoin production inhibitors and genetic material (DNA) modifiers**Amodiaquine**![](454651_1_En_8_Figp_HTML.gif){#d29e875}**Primaquine**![](454651_1_En_8_Figq_HTML.gif){#d29e888}**Chloroquine**![](454651_1_En_8_Figr_HTML.gif){#d29e901}**Etaquine**![](454651_1_En_8_Figs_HTML.gif){#d29e914}**Hydroxychloroquine**![](454651_1_En_8_Figt_HTML.gif){#d29e927}**Plasmoquine**![](454651_1_En_8_Figu_HTML.gif){#d29e940}Sulfones: inhibitors of folic acid synthesis**Dapsone**![](454651_1_En_8_Figv_HTML.gif){#d29e956}**Sulfadoxine**![](454651_1_En_8_Figw_HTML.gif){#d29e970}**Sulfalene**![](454651_1_En_8_Figx_HTML.gif){#d29e983}

The importance of drugs with the quinoline group (highlighted in bold in the structural formulas of Table [8.1](#Tab1){ref-type="table"}) is highlighted in several drugs, especially synthetic quinine derivatives that in the last century have achieved significant space in the pharmaceutical market. In addition to the antimalarial effect, recent studies have shown that the active ingredients quinolinics and derivatives presented antiviral activity (antiviral) (Achan et al. [@CR1]; [www.cureffi.org](http://www.cureffi.org)).

Despite a variety of drugs used in the treatment of malaria, *Plasmodium* species have become resistant to many compounds. Sibley and Ringwald ([@CR84]) reported that the emergence of resistance to antimalarial drugs is directly related to an enormous amount of pathogenic populations and the short time of reproduction of the parasite. In addition, the indiscriminate and extensive use of antimalarial drugs also contributes to the process of resistance.

Trying to solve this issue, the World Health Organization (WHO) recommends the use of combinations of antimalaria drugs instead of monotherapy, mainly Artemether/Lumefantrine, Artesunate/Amodiaquine, Artesunate/Mefloquine, Artesunate/Sulfadoxine, and Artesunate/Pyrimethamine (WHO [@CR95]; Cunico et al. [@CR27]). Some in vitro studies demonstrated that the compounds verapamil, desipramine, and promethazine may reverse the resistance of *P. falciparum* to chloroquine; however, the mechanisms of this reversal are not yet known (Van Schalkuyk et al. [@CR88]; Ridley [@CR03]; Cunico et al. [@CR27]).

The resistance of the parasites to the classic antimalarial drugs has enormously motivated the prospection of new drugs, and metal-based compounds play an important role in this context. Strategies for the discovery and development of metal-based drugs are driven by the elucidation of the biological profile of the parasite and by the identification of therapeutic targets. Metalloantimalarials are considered very attractive new antimalaria agents as we will see in the following topics.

Metalloantimalarials {#Sec3}
====================

Metal Complexes {#Sec4}
---------------

The use of metals for therapeutic purposes has following advantages: the possibility of preparing stable complexes with predictable structures, the selective choice of ligands according to their affinity, and the increasing know-how on the metal complexes behavior in biological environments (Allesio [@CR6]). The antimalarial activities of several metal complexes were already demonstrated, proving their high potential as alternative treatment against resistant *Plasmodium* species (Biot et al. [@CR14]; Salas et al. [@CR79]; Wani et al. [@CR91]).

Metal Complexes of Quinoline {#Sec5}
----------------------------

The attachment of a metal atom to an already existent antimalarial drug is an interesting strategy used to enhance its efficacy (Navarro [@CR63]). Quinoline-containing antimalarial drugs are widely used in malaria therapy, as mentioned in Table [8.1](#Tab1){ref-type="table"} (Salas et al. [@CR79]).

Chloroquine (CQ) and aminoquinoline were extensively used for many years (Sharma [@CR83]; Navarro et al. [@CR66]). Ruthenium complexes, widely investigated for many applications in medicine, exhibit anticancer, anti-allergic, and antiparasitic potential, as they correspond to nitric oxide donors for vascular relaxation induction (Donnici et al. [@CR30]; Levina et al. [@CR51]; Gambino and Otero [@CR38]; Lima et al. [@CR53]; Seuanes et al. [@CR82]; Correa et al. [@CR25]; Furrer et al. [@CR37]; Mazuryk et al. [@CR59]; Zhang et al. [@CR98]). The synthesis of ruthenium complexes containing CQ as ligands is an interesting strategy to improve the effectiveness of antimalarial drugs (Sanchez-Delgado et al. [@CR80]; Biot et al. [@CR13]; Martínez et al. [@CR58]).

Historically, ruthenium CQ complexes were the first class of compounds investigated for this purpose. According to the literature, the binuclear complex of Ru(II) chloroquine \[RuCQCl~2~\]~2~ (**complex 1**, Fig. [8.3](#Fig3){ref-type="fig"}) was five times more potent than standard chloroquine against *P. berghei* and *P. falciparum* strains. The mechanism of action of **complex 1** was described as the posthydrolytic binding to hematin in solution inhibiting its aggregation to β-hematin. Results show that the presence of the metal resulted in significantly enhanced activity against CQ-resistant strains (Sanchez-Delgado et al. [@CR80]; Martínez et al. [@CR57]; Salas et al. [@CR79]).Fig. 8.3Gold and ruthenium complexes of chloroquine

Sanches-Delgado et al. ([@CR80]) synthesized the first class of ruthenium complexes containing CQ as ligand. In vitro experiments showed that arena ruthenium complexes were more effective than CQ against resistant strains of *P. falciparum.* Arene-Ru(II)-chloroquine (**complexes 2**--**4**, Fig. [8.3](#Fig3){ref-type="fig"}) demonstrated appreciable antimalarial activity. Additionally, the interaction between these ruthenium derivatives and target biomolecules was investigated (Martínez et al. [@CR58]).

Another promising class of chloroquine complexes for the development of therapeutic agents are gold complexes (Navarro [@CR63]; Navarro et al. [@CR66]). These compounds exhibit antiparasitic potential for the treatment of leishmaniasis, trypanosomiasis, schistosomiasis, and malaria (Fricker et al. [@CR36]; Navarro [@CR63]; Vieites et al. [@CR90]; Navarro et al. [@CR66]; Biot et al. [@CR14]).

The antiplasmodial potential of gold complexes was investigated, with a high number of possible ligands that can be coordinated to CQ or chloroquine diphosphate (CQDP), allowing the investigation of antimalarial properties of the several complexes (Navarro [@CR63]).

In vitro tests showed that the gold complex \[Au(PPh~3~)(CQ)\]PF~6~ (**complex 5**, Fig. [8.3](#Fig3){ref-type="fig"}) caused inhibition of two resistant strains of *P. falciparum*, with IC~50~ values of 5 and 23 nM, and against a *P. berghei* strain. Studies on the elucidation of the possible mechanism of action of this complex include two targets, i.e., the inhibition of hemozoin (malarial pigment) and DNA interaction. Experiments with mice showed that treatment 1 mg/kg of AuCQ, and parallely with equivalent concentrations of CQDP, induced a reduction in parasite cells of 84 and 44%, respectively, when compared to the untreated control. These results suggest that the complexation of gold to CQ increased the in vivo susceptibility of *P. berghei* to CQ (Navarro et al. [@CR64], [@CR67]) and lead to the search for novel gold--CQ complexes, which were synthesized, characterized, and evaluated against CQ-sentitive and CQ-resistant strains of *P. falciparum*. In this perspective, changes in the molecular structure of the \[Au(PPh~3~)(CQ)\]PF~6~ complex were performed, such as variation in the counter anion (**complex 6**, Fig. [8.3](#Fig3){ref-type="fig"}), in the phosphine ligand (**complex 7**, Fig. [8.3](#Fig3){ref-type="fig"}), and in gold oxidation state (Au (I) and Au (III)) (Navarro et al. [@CR64], [@CR65]).

The literature also reported the antimalarial activities of iron, cobalt, and nickel complexes containing chloroquine (CQ) and Mefloquine (Mef) as ligands. The complexes of general formula \[M(II)L~1~L~2~Cl~2~\] and \[M(III)(Mef)(CQ)Cl~3~)\], where L~1~ = Mefloquine, L~2~ = chloroquine, M = Co^2+^, Ni^2+^, and Fe^3+^, were synthesized, characterized, and evaluated. The in vivo tests revealed that the mixed metal complexes of Mefloquine and chloroquine \[Co(Mef)(CQ)Cl~2~\] and \[Fe(Mef)(CQ)Cl~3~)\] exhibited higher antimalarial potential. Furthermore, toxicity studies showed that these complexes demonstrated less toxicity than the Ni(II) analogue (Adediji et al. [@CR4]). Other quinoline derivatives, Amodiaquine and primaquine, were complexed to several metal ions. The complexes of general formula \[M^2+^(Amodiaquine)(Cl)~2~\] and \[Mn^+^(primaquine)~2~(X)~n~(H~2~O)~y~\], where M= VO(II), Cr(III), Fe(III), Cu(II), Co(II), Ni(II), Zn(II), Cd(II), Hg(II), Rh(III), Pd(II), Au(III), Ag(I), Mn(II), Sn(II), and Pt(II), were prepared and studied as potential antimalarial agents (Wasi et al. [@CR92]). The antimalarial activity of platinum (II) complexes containing 4-aminoquinoline analogues was also considered (Souza et al. [@CR86]). All these results indicated that metal complexation to traditional antimalarial quinolones represents an attractive alternative to the development of new antimalarials agents.

Metal Complexes of Other Ligands {#Sec6}
--------------------------------

In a very informative review on gallium(III) complexes as new promising metal-based drug candidates, Lessa et al. ([@CR50]) mentioned the complex of general formula \[Ga-3-Madd\]ClO~4~, where H~2~-3-Madd = 1,12 bis-(2-hydroxy-3-methoxybenzyl)-1,5,8,12-tetraazododecane, active against chloroquine-resistant FCR-3 and Indo-1 lineages at low micromolar concentrations. The complexes \[Fe-3-Eadd\]ClO~4~ (**complex 8**, Fig. [8.4](#Fig4){ref-type="fig"}) and \[Ga-3-Eadd\]ClO~4~ (**complex 9**, Fig. [8.4](#Fig4){ref-type="fig"}), where H~2~-3-Eadd = 1,12-bis-(2-hydroxy-3-ethyl-benzyl-1,5,8,12-tetraazadodecane, were investigated in respect to their antimalarials activities against HB3 (chloroquine-sensitive) and Dd2 (chloroquine-resistant) *P. falciparum* strains. The results revealed that both complexes were effective against the HB3 chloroquine-resistant strains, but were 10--30 times less potent against Dh2 chloroquine-resistant strains. In the case of HB3 strains, both complexes were good inhibitors of hemozoin formation and modest to Dh2 strain. According to the authors, these results suggested that due to the similar antimalarial activities of the complexes, gallium(III) can replace iron(III) in biological environments.Fig. 8.4Chemical structure of some metal complexes with antimalarial activity

The structure--activity correlation of some metallic antimalarial complexes was studied. A series of copper (II) complexes containing naphthoquinone ligands were synthesized, characterized, and evaluated. All complexes exhibit enhanced antimalarial activity against 3D7 *P. falciparum* strains. Furthermore, correlations between the antimalarial activity and the metal redox couple indicate the component of the parasitic electron transport chain as a possible target of such compounds (Gokhale et al. [@CR41]). Complexes containing buparvaquone of general formula \[M(II)(L1)~2~(C2H~5~OH)~2~\], where M(II) = Cu, Co, Ni, Mn, and Fe and L1 = buparvaquone ({3-trans-(4-tert-butylcyclohexyl) methyl-2-hydroxy-1,4-naphthoquinone}), were studied (Gokhale et al. [@CR40]). The copper complex that showed better results demonstrated a thousand-fold enhancement in the antimalarial activity of parent quinone against 3D7 strain. Furthermore, this complex was three times more active against the chloroquine-resistant *P. falciparum* K1 strain when compared to the free ligand. Experiments with this strain cellular showed a 90% reduction in parasitemia at a dose of 15 mg/kg, which demonstrates the high potential of the copper complex as antimalarial agent (Gokhale et al. [@CR40]). The antimalarial activity of gold(I) thiosemicarbazone complexes (**complexes 10** and **11**, Fig. [8.4](#Fig4){ref-type="fig"}) and platinum (II) and palladium(II) complexes with ligands derived from pyrazole (**complexes 12**--**15**, Fig. [8.4](#Fig4){ref-type="fig"}) was also investigated. These complexes exhibited better efficacy in comparison to their free ligands against D10, W2, and 3D7 strains of *P. falciparum* (Khanye et al. [@CR46]; Quirante et al. [@CR73]). Besides the enhancement of the efficacy of organic drugs, the metal complexes correspond to new alternatives for the treatment of malaria, such as the inhibition of the parasite establishment in the vector mosquito.

Recently, Tapanelli et al. ([@CR87]) showed that Cu(I), Au(I), and Ag(I) phosphene complexes exhibited notable activity against the *Plasmodium* early sporogonic stages. The results showed that the metal complexes of general formula \[M(L)~4~\]PF~6~ (M = Cu(I), Ag(I) and \[Au(L)~4~\]Cl with L = Thp (tris(hydroxymethyl) phosphene) or PTA (1,3,5-triaza-7-phosphaadamantane) interfere with the early sporogonic stage of *Plasmodium,* inhibiting the parasite establishment in the vector mosquito.

Metal Chelators {#Sec7}
---------------

All microorganisms need iron for their growth and replication (Crumbliss [@CR26]). Several metabolic processes of the erythrocytic malaria parasite are dependent on iron, such as heme synthesis, DNA synthesis, proteolysis of hemoglobin, glycolysis pentose phosphate shunt, mitochondrial electron transport, and CO~2~ fixation. It is therefore an indication that capturing iron from the parasite may interfere negatively on its metabolism (Sharma [@CR83]).

This strategy corresponds to an interesting alternative for malaria treatment. Common iron-chelating compounds are siderophore, naturally produced by microorganisms to acquire iron from the environment. These compounds can also be administered in the form of free ligands to sequestrate iron, causing the death of the parasite due to deprivation, or in the form of toxic complexes with iron that inhibit parasite growth (Mabeza et al. [@CR56]).

Some characteristics are very important for effective iron-chelating, such as a hydrophilic--hydrophobic balance, the structure of the hex dentate ligand, a selectivity for iron(III), and high affinity for iron and for others cations. The affinity for iron is a main prerequisite for antimalarial activity of an iron-chelating drug, with values of affinity constants iron(III) chelators ranging from 10^24^ to 10^38^, according to the literature. The classic chelator desferrioxamine (DFO) (**complex 16**, Fig. [8.5](#Fig5){ref-type="fig"}), for example, presents an affinity constant value of 10^31^, forming a stable complex with iron and, therefore, a high antimalarial activity. The chelator must have additional affinity for other metals such as calcium, magnesium, and zinc, as their removal may be detrimental for the parasite (Goodwin and Whitten [@CR42]; Albert [@CR5]; Lytton et al. [@CR55]; Ponka et al. [@CR71]; Cabantchik et al. [@CR20]).Fig. 8.5Metal chelators used for malaria

The intensity of the antimalarial activity of iron chelators correlates with their hydrophilic/hydrophobic balance, as they can be capable of permeating cell membranes (Scheibel and Rodriguez [@CR81]). Experimental studies with amino-terminal derivatives of desferrioxamine showed a preserved ability to bind to iron(III) species and a corresponding reduction to bind to iron(II) (Glickstein et al. [@CR39]). Moreover, iron (III) forms stable complexes with coordination number equal six (Mabeza et al. [@CR56]).

Desferrioxamine (DFO) is an important representative of iron-chelator and the first example of metal-based drug used to treat malaria. This siderophore occurs naturally in the form of trihydroxamic acid in *Streptomyces pilosus* and is used to treat hemochromatosis. However, the inherent slow permeation into infected cells and the restriction to advanced stages of *P. falciparum* are examples of drawbacks that limit its application (Modell and Berdoukas [@CR62]; Brittenham [@CR18]), and some structural modifications were conducted to produce more active and lipophilic derivatives, with broader efficiency for different stages of the infected cells.

As example of this strategy, a more lipophilic complex (MA-DFO, **complex 17**, Fig. [8.5](#Fig5){ref-type="fig"}) was synthesized by attaching N-methylanthranilic acid to the N-terminus, leading to a higher antimalarial activity. Zinc--desferrioxamine (Zn-DFO) complex exhibited increased permeability and improved antimalarial activity when compared to free DFO. A metal substitution reaction occurs inside the erythrocyte, forming the Fe(III)-DFO complex, which is more stable than the Zn-DFO complex (Loyevsky et al.[@CR54]; Chevion et al.[@CR24]).

During the last decades, the antimalarial activities of iron-chelating compounds have been investigated and metal chelators such as 1-(N-acetyl-6-aminohexyl)-3-hydroxy-2-methylpyridin-4-one demonstrated notable ability to inhibit the growth of *P. falciparum* in erythrocytes (Pangjit et al. [@CR70]). Therefore, iron chelators correspond to a promising area to explore and obtain effective metal-based drugs for malaria.

Organometallic Compounds {#Sec8}
------------------------

In organometallic compounds, a metal--carbon bond (σ or π) provides special features to classic compounds. Many of these complexes have electronic structures based in 18 valence electrons (Miessler and Tarr [@CR61]) and, due to their use in catalysis and other applications, are considerate potential therapy agents (Chavain and Biot [@CR23]).

The first organometallic compounds for application in medicine, salvarsan (arsphenamine) and neosalvarsan, were based in arsenic and reported by Paul Ehrlich to treat syphilis and trypanosomiasis (Salas et al. [@CR79]). Several organometallic complexes were prepared and valued as potential antimalarial agents, with ferrocene exhibiting the hightest antimalarial activity (Wani et al. [@CR91]). Ferrocenes are highly liposoluble, stable, and nontoxic and have accessible redox potential, which make them very attractive to therapeutic applications (Van-Staveren and Metzler-Nolte [@CR89]; Fouda et al. [@CR34]), including malaria treatment. Inspired in ferrocene, several ferrocene-conjugated analogue structures were synthesized such as Mefloquine, artemisia, mepacrine, quinine, atovaquone, and other molecules (Biot et al. [@CR04]; Blackie et al. [@CR16]; Blackie and Chibale [@CR15]).

Until the present moment, ferrochloroquine or ferroquine (FQ) (**complex 18**, Fig. [8.6](#Fig6){ref-type="fig"}) is the most successful metal-based drug for malaria therapy. This compound was described in 1997 as the first chloroquine derivative containing a ferrocene molecule, incorporating the ferrocene to the lateral side chain of chloroquine (Biot et al. [@CR9]). Although there are structural similarities between chloroquine and FQ, the in vitro activities against *P. falciparum* of these compounds are distinct. FQ has high efficiency against chloroquine-sensitive and chloroquine-resistant *P. falciparum* parasite strains, reaching efficiencies 20 times higher than chloroquine. FQ exhibited high activity in vivo against *P. yoeli, P. vinckei*, and *P. berghei* strains (Biot et al. [@CR10], [@CR05]).Fig. 8.6Chemical structure of ferroquine (FQ)

Some evidences point that the action of FQ seems to be related to inhibition of the hemozoin formation in the food vacuole of the parasite. Despite the similarity in mechanism when compared to CQ, studies indicated that FQ is more efficient than CQ to inhibit the formation of β-hematin. FQ and CQ showed IC50 values of 0.8 and 1.9, respectively (Biot et al. [@CR11]).

The ferroquine compound FQ (SSR97193) is a successful representative of an organometallic drug (Sharma [@CR83]; Biot et al. [@CR13]). Because of its good antimalarial activity, it has been the object of many studies (Barends et al. [@CR8]; Biot et al. [@CR13]; Wani et al. [@CR91]) and is now the only metal-based compound that is in phase II clinical test for malaria therapy. Daher et al. ([@CR28]) reported in vitro studies on the metabolism of ferroquine (SSR97193) in animals and humans, indicating potential applications of ferroquine in malaria therapy.

These previous interesting results stimulated the synthesis of several ferroquine derivatives, such as thiosemicarbazones, trioxaferroquines, ferrocene dual conjugates, hydroxyferroquines, and benzothiazoles (Wani et al. [@CR91]; Adams et al. [@CR3]). Thiosemicarbazones (TSCs) correspond to a very important class of compound for medicinal chemistry (Leovac et al. [@CR49]), with interesting biological effects, including antimalarial activity (Bahl et al. [@CR7]).

In vitro tests against *P. falciparum* strains demonstrated that the antiplasmodial activity of FQ conjugates and thiosemicarbazones was higher than for free thiosemicarbazone. Also, FQ-TSCs (**complex 19**, Fig. [8.7](#Fig7){ref-type="fig"}) displayed higher efficiency against four *Plasmodium* strains with IC~50~ values at micromolar range (Biot et al. [@CR12]). Hydroxyferroquine derivatives were also tested, and Wani et al. ([@CR91]) observed that they exhibited antiplasmodial activity and antiviral effects against coronavirus severe acute respiratory syndrome. Hydroxyferroquine (FQ-hydroxy) derivatives (**Complex 20**, Fig. [8.7](#Fig7){ref-type="fig"}) represent thus an excellent alternative to treat malaria infections caused by coronavirus in some specific geographical regions.Fig. 8.7Derivatives of metal complexes of ferroquine

FQ-trioxaquines (FQ-trioxa) (**Complex 21**, Fig. [8.7](#Fig7){ref-type="fig"}) are potential antiplasmodial agents. In vitro and in vivo experiments demonstrated that these compounds are highly effective against CQ-resistant strains (Wani et al. [@CR91]).

Benzothiazoles exhibit appreciable biological activity, and recently, Adams et al. ([@CR3]) evaluated antimalarial activity of ferrocenyl-containing benzothiazoles (**Complex 22**--**24**, Fig. [8.7](#Fig7){ref-type="fig"}). According to the authors, these compounds presented antiplasmodial activity against CQ-resistant and CQ-sensitive strains. They also observed that ferroquine derivatives were not able to inhibit the formation of β-hematin, indicating that FQ and its derivatives have different mechanisms of action.

The binding of active pharmacophores through covalent linkages is an interesting strategy used for the design of new antimalarial agents, such as ferrocene dual conjugates. The advantage of this strategy is the fact that it causes an increase in the conjugated molecule bioavailability, which diminishes its resistance. Some ferrocene dual conjugates demonstrated good antiplasmodial activities (Meunier [@CR60]).

The development of ferrocene chemistry led to the investigation of ruthenocene analogues as antimalarial agents. Ruthenoquine (RQ) (**complex 25**, Fig. [8.8](#Fig8){ref-type="fig"}) and its derivatives (**complexes 26** and **27**, Fig. [8.8](#Fig8){ref-type="fig"}) were synthesized and presented good inhibition of *P. falciparum* growth, with similar mechanism of action as FQ (Beagley et al. [@CR06]). All the results available up to the present moment point to an enormous potential of ferroquine and its derivatives for the development of antiplasmodial agents.Fig. 8.8Ruthenoquine and their derivative compounds

Conclusions {#Sec9}
===========

The emergence of drug-resistant strains of *Plasmodium* spp. led to an urgent need to develop more effective drugs, and metal-based drugs have been considered a promising strategy against new antiplasmodial agents. In this context, metalloantimalarials based on antimalarial drugs, metal chelators, and organometallic complexes were evaluated. Among all these compounds, ferroquine is the most successful representative, already being tested in phase II clinical trials. Studies on the physiology of the parasite allowed the understanding of the mechanisms of action of new drugs and stimulated the design of new more efficient drugs. With these studies, in the near future, it is expected that metallodrugs with low toxicity and high efficiency will be found for the treatment of neglected tropical diseases such as malaria. In addition, the production costs and the final product are extremely important factors, since this guarantees the accessibility of the population of poor countries affected by these diseases.

The authors thank FAPESP (process number 15/06238-4) and CNPq (process number 304826/2013-8) for the financial support of research carried out in our laboratories.
